The need to control chronic, non-infectious uveitis without the long-term toxicity of corticosteroids has driven the essential role of steroid-sparing immunosuppressive agents. These drugs, which include antimetabolites like methotrexate and mycophenolate mofetil, and calcineurin inhibitors like cyclosporine, modulate the systemic immune response to control inflammation in the eye. They are typically initiated once the acute inflammation has been stabilized by corticosteroids.

The primary goal of using these agents is to allow the clinician to safely taper the patient off high-dose oral steroids while maintaining inflammation control. This strategy is critical for preventing irreversible side effects, such as osteoporosis, diabetes, and severe ocular complications like steroid-induced glaucoma and cataracts. While these traditional immunosuppressants also carry their own risks, such as liver toxicity or kidney issues, they provide a necessary bridge for long-term maintenance therapy in chronic cases.

The continuous search for safer and more effective maintenance options ensures that the immunosuppressant class remains a cornerstone of long-term care for severe ocular disease. The demand for these agents is a consistent driver within the therapeutic segment of the Uveitis Drug Market environment.

FAQ 1: What does "steroid-sparing" mean in this context? It means using a second class of medication (like methotrexate) that allows the patient to reduce or stop their use of high-dose corticosteroids, thereby avoiding the serious long-term side effects of steroids.

FAQ 2: When is a patient typically started on an immunosuppressive agent? They are usually started after the initial acute inflammation has been brought under control with a rapid-acting steroid, with the goal of maintaining control during the long-term phase.

Explore more reports from MRFR: